(Q33404780)

26 July 2017

title

A phase II trial of oral gimatecan for recurrent glioblastoma (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

2

Patrick Y Wen

1 reference

26 July 2017

3

Lauren E Abrey

1 reference

26 July 2017

Jethro Hu

1

1 reference

26 July 2017

Camilo E Fadul

4

1 reference

26 July 2017

Jan Drappatz

5

1 reference

26 July 2017

Nadia Salem

6

1 reference

26 July 2017

Jeffrey G Supko

7

1 reference

26 July 2017

Fred Hochberg

8

1 reference

26 July 2017

publication date

12 December 2012

1 reference

Journal of Neuro-Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

111

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

347-353

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Irinotecan therapy in adults with recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-1023-0

Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts

21 January 2018

1 reference

12 December 2020

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

1 reference

12 December 2020

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

1 reference

12 December 2020

Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin

1 reference

12 December 2020

Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer

1 reference

12 December 2020

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content

1 reference

12 December 2020

Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

1 reference

12 December 2020

10.1007/S11060-012-1023-0

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1017514108

0 references

1 reference